Table 2 Survival outcomes according to each genetic subset in both age groups.

From: Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group

 

OS

EFS

Genetic group

Overall cohort

18–60 yrs.

61–70 yrs.

p

Overall cohort

18–60 yrs

61–70 yrs.

p

CBFB::MYH11 (n)

58

44

14

     

 4-year rate (% ± sd)

60 ± 7

66 ± 8

43 ± 13

0.016

48 ± 7

52 ± 8

36 ± 13

0.034

 Median time (months)

NR

NR

4

 

41

NR

4

 

RUNX1::RUNX1T1 (n)

59

48

11

     

 4-year rate (% ± sd)

73 ± 7

75 ± 7

66 ± 16

0.39

57 ± 7

58 ± 8

51 ± 16

0.47

 Median time (months)

NR

NR

NR

 

NR

NR

NR

 

CEBPAbi (n)

17

13

4

     

 4-year rate (% ± sd)

86 ± 10

81 ± 13

100 ± 0

0.41

68 ± 12

59 ± 14

100 ± 0

0.17

 Median time (months)

NR

NR

NR

 

NR

NR

NR

 

NPM1mut/FLT3wt (n)

194

108

86

     

 4-year rate (% ± sd)

68 ± 4

76 ± 5

58 ± 6

0.033

57 ± 4

61 ± 5

50 ± 6

0.087

 Median time (months)

NR

NR

72

 

70

NR

49

 

NPM1mut/FLT3low (n)

55

39

16

     

 4-year rate (% ± sd)

77 ± 6

81 ± 7

68 ± 12

0.23

65 ± 7

70 ± 8

55 ± 13

0.16

 Median time (months)

NR

NR

NR

 

NR

NR

NR

 

Normal karyotype (n)

123

68

55

     

 4-year rate (% ± sd)

34 ± 5

47 ± 7

20 ± 6

0.02

29 ± 4

39 ± 6

15 ± 6

0.079

 Median time (months)

22

33

19

 

12

16

12

 

Other intermediate (n)

140

96

44

     

 4-year rate (% ± sd)

33 ± 4

36 ± 5

26 ± 7

0.15

28 ± 4

29 ± 5

26 ± 7

0.29

 Median time (months)

16

19

12

 

12

15

9

 

NPM1mut/FLT3high (n)

87

64

23

     

 4-year rate (% ± sd)

43 ± 6

49 ± 7

30 ± 10

0.05

37 ± 6

41 ± 7

26 ± 9

0.14

 Median time (months)

20

45

10

 

13

19

9

 

t(6;9); DEK::NUP214 (n)

9

9

0

     

 4-year rate (% ± sd)

56 ± 17

56 ± 17

 

—

56 ± 17

56 ± 17

 

—

 Median time (months)

NR

NR

  

NR

NR

  

t(v;11q23.3); KMT2A (n)

21

15

6

     

 4-year rate (% ± sd)

43 ± 12

59 ± 13

0

0.033

24 ± 12

35 ± 14

0

0.35

 Median time (months)

28

98

10

 

13

16

9

 

-5/del(5q)/-7 no CK (n)

22

13

9

     

 4-year rate (% ± sd)

44 ± 11

51 ± 15

33 ± 16

0.52

36 ± 10

39 ± 14

33 ± 16

0.78

 Median time (months)

33

74

21

 

14

8

16

 

Dysplasia-related mutations (n)

89

49

40

     

 4-year rate (% ± sd)

41 ± 7

58 ± 7

18 ± 9

<0.001

37 ± 6

52 ± 7

19 ± 7

0.0015

 Median time (months)

25

NR

17

 

15

56

8

 

MECOMr (n)

21

14

7

     

 4-year rate (% ± sd)

20 ± 9

23 ± 12

14 ± 13

0.9

16 ± 8

17 ± 11

14 ± 13

0.76

 Median time (months)

7

7

9

 

5

4

5

 

CK/MK/TP53alt (n)

132

74

58

     

 4-year rate (% ± sd)

14 ± 3

17 ± 4

10 ± 4

0.21

10 ± 3

13 ± 4

7 ± 4

0.49

 Median time (months)

9

10

9

 

7

7

7

 

Other adverse (n)

7

6

1

     

 4-year rate (% ± sd)

57 ± 19

67 ± 19

0

0.18

57 ± 19

67 ± 19

0

0.18

 Median time (months)

NR

NR

0.5

 

NR

NR

0.5

 
  1. mut mutated, wt wild-type, low: 0.5, CK complex karyotype, MK monosomal karyotype.
Back to article page